ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 317 filers reported holding ROYALTY PHARMA PLC in Q3 2022. The put-call ratio across all filers is 0.29 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $8,107,044 | -52.4% | 298,712 | -46.1% | 1.89% | -53.3% |
| Q2 2023 | $17,021,261 | -18.4% | 553,717 | -4.3% | 4.04% | -26.0% |
| Q1 2023 | $20,853,551 | -13.4% | 578,783 | -5.0% | 5.46% | -22.0% |
| Q4 2022 | $24,081,591 | -4.7% | 609,352 | -3.1% | 7.00% | -2.5% |
| Q3 2022 | $25,269,000 | -14.1% | 628,902 | -10.2% | 7.18% | -15.6% |
| Q2 2022 | $29,431,000 | +4.4% | 700,071 | -3.2% | 8.50% | +36.1% |
| Q1 2022 | $28,178,000 | -3.0% | 723,250 | -0.8% | 6.25% | +6.6% |
| Q4 2021 | $29,056,000 | +2.4% | 729,125 | -7.1% | 5.86% | -4.9% |
| Q3 2021 | $28,375,000 | -8.6% | 785,132 | +3.7% | 6.16% | -5.0% |
| Q2 2021 | $31,034,000 | -7.7% | 757,121 | -1.8% | 6.49% | -13.3% |
| Q1 2021 | $33,638,000 | -13.7% | 771,155 | -0.9% | 7.48% | -21.3% |
| Q4 2020 | $38,964,000 | +759.6% | 778,511 | +622.5% | 9.50% | +808.7% |
| Q3 2020 | $4,533,000 | – | 107,752 | – | 1.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SIGULER GUFF ADVISERS, LLC | 6,761,970 | $244,378,000 | 79.54% |
| Vantage Consulting Group Inc | 7,862,542 | $284,152,000 | 60.85% |
| Memorial Sloan Kettering Cancer Center | 2,680,644 | $96,878,000 | 60.36% |
| Indie Asset Partners, LLC | 701,323 | $25,346,000 | 20.53% |
| HARVARD MANAGEMENT CO INC | 7,142,856 | $258,143,000 | 15.13% |
| Bleichroeder LP | 1,115,980 | $40,332,000 | 6.55% |
| Overbrook Management Corp | 785,132 | $28,375,000 | 6.16% |
| Geo Capital Gestora de Recursos Ltd | 194,305 | $7,022,000 | 3.21% |
| Brown University | 621,759 | $22,470,000 | 3.05% |
| Graypoint LLC | 610,584 | $22,067,000 | 2.71% |